TXG Valuation

10X Genomics Inc

Add to Watchlist

Advanced Chart

14.110

+0.38(2.768%)1D

Overview
Forecast
Valuation
Earnings

TXG Relative Valuation

TXG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TXG is overvalued; if below, it's undervalued.

Historical Valuation

10X Genomics Inc (TXG) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.13 is considered Undervalued compared with the five-year average of -113.20. The fair price of 10X Genomics Inc (TXG) is between 25.36 to 156.30 according to relative valuation methord. Compared to the current price of 13.77 USD , 10X Genomics Inc is Undervalued By 45.72%.

Relative Value

Fair Zone

25.36-156.30

Current Price：13.77

45.72%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.76

P/B

Median3y

5.09

Median5y

11.10

3.65

FCF Yield

Median3y

-1.64

Median5y

-1.54

Competitors Valuation Multiple

The average P/S ratio for TXG's competitors is 8.64, providing a benchmark for relative valuation. 10X Genomics Inc Corp (TXG) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 9.84%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap